Valion Bio, Inc. (VBIO): Valuation
TTM figures as of March 30, 2026
Valion Bio, Inc. trades at a -306.49% free-cash-flow yield. That FCF yield is higher than 37% of its own month-end history back to 2021.
Earnings yield -367.71%. ROIC -45.1%. Piotroski F-score 4 of 9. Net cash $316.0K.
57 month-end valuation observations are on file, starting December 2021.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is VBIO cheap versus its own history?
Valion Bio, Inc. trades at a -306.49% free-cash-flow yield. That FCF yield is higher than 37% of its own month-end history back to 2021.
What is VBIO's free-cash-flow yield?
Valion Bio, Inc. currently yields -306.49% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.